keyword
MENU ▼
Read by QxMD icon Read
search

Ceftaroline

keyword
https://www.readbyqxmd.com/read/27918694/ceftaroline-activity-against-multidrug-resistant-streptococcus-pneumoniae-from-u-s-medical-centers-2014-and-molecular-characterization-of-a-single-ceftaroline-nonsusceptible-isolate
#1
Michael A Pfaller, Rodrigo E Mendes, Robert K Flamm, Ronald N Jones, Helio S Sader
Streptococcus pneumoniae isolates (2,614) were collected from patients at 135 U.S. Medical Centers during 2014. Isolates were evaluated for multidrug resistance to penicillin, ceftriaxone, erythromycin, tetracycline, trimethoprim-sulfamethoxazole, and levofloxacin. A single isolate (853008) demonstrated a ceftaroline nonsusceptible minimal inhibitory concentration (MIC) value, and it was subjected to molecular characterization. Ceftaroline (MIC50/90, ≤0.015/0.12 μg/ml) was eightfold more potent than ceftriaxone (MIC50/90, ≤0...
December 5, 2016: Microbial Drug Resistance: MDR: Mechanisms, Epidemiology, and Disease
https://www.readbyqxmd.com/read/27895012/a-multicenter-observational-study-of-ceftaroline-fosamil-for-methicillin-resistant-staphylococcus-aureus-bloodstream-infections
#2
Evan J Zasowski, Trang D Trinh, Kimberly C Claeys, Anthony M Casapao, Noor Sabagha, Abdalhamid M Lagnf, Kenneth P Klinker, Susan L Davis, Michael J Rybak
Novel therapies for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI) are needed in the setting of reduced antibiotic susceptibilities and therapeutic failure. Ceftaroline is an advanced generation cephalosporin with MRSA activity. Although not FDA approved for MRSA BSI, ceftaroline has generated much interest as a potential treatment option. However, detailed description of its use in this setting remains limited. To address this, we conducted a retrospective, multicenter, observational study of adult patients with MRSA BSI treated with at least 72 hours of ceftaroline from 2011 to 2015...
November 28, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27890418/comparative-in-vitro-activity-of-oritavancin-and-other-agents-against-methicillin-susceptible-and-methicillin-resistant-staphylococcus-aureus
#3
Debora Sweeney, Dean L Shinabarger, Francis F Arhin, Adam Belley, Greg Moeck, Chris M Pillar
Methicillin-resistant Staphylococcus aureus (MRSA) infections constitute a threat to the public health due to their prevalence and associated mortality and morbidity. Several agents have been recently approved to treat MRSA skin infections including lipoglycopeptides (dalbavancin, oritavancin, and telavancin), ceftaroline, and tedizolid. This study compared the MIC, minimum bactericidal concentration (MBC), and time-kill of these agents alongside daptomycin, linezolid, and vancomycin against MRSA (n=15); meropenem, cefazolin, and nafcillin were also included against methicillin-susceptible S...
November 12, 2016: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/27889013/methicillin-resistant-staphylococcus-aureus-infections-a-review-of-the-currently-available-treatment-options
#4
REVIEW
S M Purrello, J Garau, E Giamarellos, T Mazzei, F Pea, A Soriano, S Stefani
This review is the result of discussions that took place at the 5th MRSA Working Group Consensus Meeting and explores the possible treatment options available for different types of infections due to methicillin-resistant Staphylococcus aureus (MRSA), focusing on those antibiotics that could represent a valid alternative to vancomycin. In fact, whilst vancomycin remains a viable option, its therapy is moving towards individualised dosing. Other drugs, such as the new lipoglycopeptides (oritavancin, dalbavancin and telavancin) and fifth-generation cephalosporins (ceftaroline and ceftobiprole), are showing good in vitro potency and in vivo efficacy, especially for patients infected with micro-organisms with higher vancomycin minimum inhibitory concentrations (MICs)...
December 2016: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/27873126/resistance-to-non-glycopeptide-agents-in-serious-staphylococcus-aureus-infections
#5
REVIEW
Kyle C Molina, Vanthida Huang
The role of vancomycin in the treatment of serious Staphylococcus aureus infections, both methicillin-susceptible and methicillin-resistant, is becoming increasingly ineffective due to increasing MIC and failure. The development of reduced vancomycin susceptibility by S. aureus to glycopeptides highlights the need for clinicians to reexamine the roles of non-glycopeptide therapy. As the use of these alternative non-glycopeptides antimicrobials increases, it will become pertinent to monitor the rates of resistance...
December 2016: Current Infectious Disease Reports
https://www.readbyqxmd.com/read/27856079/in-vitro-activity-of-ceftobiprole-on-440-staphylococcus-aureus-strains-isolated-from-bronchopulmonary-infections
#6
E Hodille, L Delouere, C Bouveyron, H Meugnier, M Bes, A Tristan, F Laurent, F Vandenesch, G Lina, O Dumitrescu
OBJECTIVE: We assessed the in vitro activity of ceftobiprole on 440 Staphylococcus aureus clinical strains isolated from bronchopulmonary infections (2010-2014). METHODS: S. aureus isolates were characterized for methicillin resistance, PVL status, and clonal complex. All isolates were tested for minimal inhibitory concentrations (MIC) determination by broth microdilution method for ceftobiprole, ceftaroline fosamil, and comparator antibiotics (linezolid, tigecycline, vancomycin, and daptomycin)...
November 14, 2016: Médecine et Maladies Infectieuses
https://www.readbyqxmd.com/read/27850314/675-clinical-experience-with-ceftaroline-fosamil-in-the-intensive-care-unit
#7
George Udeani, Timothy Pasquale, Keith Kaye, Alena Jandourek
No abstract text is available yet for this article.
December 2016: Critical Care Medicine
https://www.readbyqxmd.com/read/27798220/etest%C3%A2-versus-broth-microdilution-for-ceftaroline-mic-determination-with-staphylococcus-aureus-results-from-premium-a-european-multicentre-study
#8
Rafael Cantón, David M Livermore, María Isabel Morosini, Jazmín Díaz-Regañón, Gian Maria Rossolini
OBJECTIVES: To compare the concordance of ceftaroline MIC values by reference broth microdilution (BMD) and Etest (bioMérieux, France) for MSSA and MRSA isolates obtained from PREMIUM (D372SL00001), a European multicentre study. METHODS: Ceftaroline MICs were determined by reference BMD and by Etest for 1242 MSSA and MRSA isolates collected between February and May 2012 from adult patients with community-acquired pneumonia or complicated skin and soft tissue infections; tests were performed across six European laboratories...
October 20, 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27769972/physical-compatibility-of-tedizolid-phosphate-with-selected-i-v-drugs-during-simulated-y-site-administration
#9
Islam Ghazi, Yukihiro Hamada, David P Nicolau
PURPOSE: The physical compatibility of commonly used agents that could be coadministered in the clinical setting with tedizolid phosphate during Y-site administration was evaluated. METHODS: Tedizolid phosphate vials were reconstituted to a final concentration of 0.8 mg/mL. All other drugs were prepared according to manufacturers' recommendations and diluted with 0.9% sodium chloride injection (where applicable) to the highest standard concentrations used clinically...
November 1, 2016: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/27766567/ceftaroline-fosamil-a-review-in-complicated-skin-and-soft-tissue-infections-and-community-acquired-pneumonia
#10
Lesley J Scott
Intravenous ceftaroline fosamil (Zinforo™), a prodrug that is rapidly converted to its active metabolite ceftaroline, is approved for use in adults and children (from 2 months of age) with complicated skin and soft tissue infections (cSSTIs) or community-acquired pneumonia (CAP). In several multinational trials, ceftaroline fosamil was an effective and generally well tolerated treatment in adult and paediatric patients with cSSTIs or CAP. In the phase 3 CANVAS trials, ceftaroline fosamil treatment was noninferior to vancomycin plus aztreonam in adults with cSSTIs...
November 2016: Drugs
https://www.readbyqxmd.com/read/27744604/antimicrobial-activity-of-ceftaroline-against-methicillin-resistant-staphylococcus-aureus-mrsa-isolates-collected-in-2013-2014-at-the-geneva-university-hospitals
#11
D O Andrey, P François, C Manzano, E J Bonetti, S Harbarth, J Schrenzel, W L Kelley, A Renzoni
Ceftaroline is a broad-spectrum antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA) strains. Ceftaroline susceptibility of an MRSA set archived between 1994 and 2003 in the Geneva University Hospitals detected a high percentage (66 %) of ceftaroline resistance in clonotypes ST228 and ST247 and correlated with mutations in PBP2a. The ceftaroline mechanism of action is based on the inhibition of PBP2a; thus, the identification of PBP2a mutations of recently circulating clonotypes in our institution was investigated...
October 15, 2016: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/27721280/in-vitro-activity-of-ceftaroline-a-novel-antibiotic-against-methicillin-resistant-staphylococcus-aureus
#12
Vaishali Gaikwad, Tejash Gohel, Shrijeet Panickar, Vijay Chincholkar, Santosh Mangalkar
INTRODUCTION: Staphylococcus is one of the most common causes of nosocomial infection, especially pneumonia, surgical site infections, blood stream infections, and continues to be a major cause of community-acquired infections. The emergence of penicillin resistance followed by the development and spread of strains resistant to the semisynthetic penicillins such as methicillin, oxacillin and nafcillin, macrolides, tetracycline, and aminoglycosides has made the treatment of staphylococcal infection a global challenge...
October 2016: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/27634917/in-vitro-activity-of-ceftaroline-against-clinical-staphylococcus-aureus-isolates-collected-during-a-national-survey-conducted-in-belgian-hospitals
#13
M Angeles Argudín, M Dodémont, M Taguemount, S Roisin, R de Mendonça, A Deplano, C Nonhoff, O Denis
OBJECTIVES: The aim of this study was to estimate the in vitro activity of ceftaroline against clinical Staphylococcus aureus isolates collected during national surveillance in Belgian acute-care hospitals. Ceftaroline-resistant isolates were further investigated for their resistance mechanisms. METHODS: From October 2013 to March 2014, 155 laboratories of Belgian acute-care hospitals were invited to send to the National Reference Centre-Staphylococcus aureus (Belgium) up to five non-duplicate S...
September 15, 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27585969/a-phase-iii-randomized-controlled-non-inferiority-trial-of-ceftaroline-fosamil-600-mg-every-8-h-versus-vancomycin-plus-aztreonam-in-patients-with-complicated-skin-and-soft-tissue-infection-with-systemic-inflammatory-response-or-underlying-comorbidities
#14
Matthew Dryden, Yingyuan Zhang, David Wilson, Joseph P Iaconis, Jesus Gonzalez
OBJECTIVES: Increasing the ceftaroline fosamil dose beyond 600 mg every 12 h may provide additional benefit for patients with complicated skin and soft tissue infections (cSSTIs) with severe inflammation and/or reduced pathogen susceptibility. A Phase III multicentre, randomized trial evaluated the safety and efficacy of ceftaroline fosamil 600 mg every 8 h in this setting. METHODS: Adult patients with cSSTI and systemic inflammation or comorbidities were randomized 2:1 to intravenous ceftaroline fosamil (600 mg every 8 h) or vancomycin (15 mg/kg every 12 h) plus aztreonam (1 g every 8 h) for 5-14 days...
September 1, 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27559120/comparative-in-vitro-activities-of-ceftaroline-and-ceftriaxone-against-bacterial-pathogens-associated-with-respiratory-tract-infections-results-from-the-aware-surveillance-study
#15
D J Biedenbach, J P Iaconis, D F Sahm
OBJECTIVES: Ceftaroline fosamil is indicated for the treatment of community-acquired bacterial pneumonia and ceftriaxone has an indication for lower respiratory tract infections. This study was conducted to compare the relative in vitro activities of these two agents against bacterial species associated with community-associated respiratory tract infections. METHODS: In all, 13 005 isolates of Staphylococcus aureus, Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae were collected in 2012-14 from 39 countries in the Asia-Pacific region, Europe, Latin America and Africa-Middle East from respiratory tract specimens...
August 23, 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27553740/in-vitro-ceftaroline-combinations-against-meticillin-resistant-staphylococcus-aureus
#16
Ana Belén García, Francisco Javier Candel, López Lopez, Flavia Chiarella, José Manuel Viñuela-Prieto
We studied in vitro ceftaroline combinations against 61 meticillin-resistant Staphylococcus aureus isolates; 18 of them were also resistant to linezolid, using overlapping E-test method. Daptomycin-ceftaroline combination obtained lower fractional inhibitory concentration values, in comparison with those including vancomycin or linezolid against meticillin-resistant S. aureus (P<0.05). All meticillin- and linezolid-resistant S. aureus strains were resistant to ceftaroline; nevertheless, combinations with vancomycin or daptomycin showed higher synergy or addition rates than those with linezolid...
October 2016: Journal of Medical Microbiology
https://www.readbyqxmd.com/read/27530754/outpatient-use-of-ceftaroline-fosamil-versus-vancomycin-for-osteoarticular-infection-a-matched-cohort-study
#17
Vasilios Athans, Rachel M Kenney, Jacob Wong, Susan L Davis
OBJECTIVES: There are few convenient intravenous options for long-term outpatient treatment of osteoarticular infection (OAI) and limited effectiveness and safety data exist for this off-label use of ceftaroline. The objective of this study was to describe the long-term effectiveness and safety of ceftaroline for the treatment of OAI. METHODS: This was a matched retrospective cohort study of patients receiving ceftaroline- or vancomycin-based therapy for OAI in the outpatient setting...
August 15, 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27526275/ceftaroline-plus-ampicillin-against-gram-positive-organisms-results-from-e-test-synergy-assays
#18
Silvia D'Arezzo, Antonio Mazzarelli, Carolina Venditti, Carla Nisii, Nicola Petrosillo, Chiara De Giuli, Antonella Vulcano, Maria Grazia Paglia, Eugenio Bordi, Antonino Di Caro, Fabrizio Taglietti
In an era of increasing drug resistance and limited numbers of antimicrobials in the drug production pipeline, healthcare-associated infections represent a growing public health threat. When therapeutic options are limited, clinicians often resort to using antimicrobial combinations that produce a synergistic effect on the target pathogen. Novel antibiotics are therefore welcome in the daily practice of medicine. For example, ceftaroline is a broad-spectrum cephalosporin active against a variety of bacteria, including methicillin-resistant Staphylococcus aureus, but with limited activity against enterococci, particularly Enterococcus faecium...
August 15, 2016: Microbial Drug Resistance: MDR: Mechanisms, Epidemiology, and Disease
https://www.readbyqxmd.com/read/27520326/ceftaroline-as-salvage-monotherapy-for-persistent-mrsa-bacteremia-a-review-of-current-literature
#19
Yvonne J Burnett, Kelly Echevarria, Kristi A Traugott
OBJECTIVE: To summarize published data regarding the use of ceftaroline as salvage monotherapy for persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. DATA SOURCES: PubMed (January 1980-June 2016) was searched using combinations of the search terms methicillin-resistant Staphylococcus aureus, MRSA, bacteremia, ceftaroline, refractory, and persistent Supplemental references were generated through review of identified literature citations. STUDY SELECTION AND DATA EXTRACTION: Available English-language, full-text articles pertaining to the use of ceftaroline for persistent MRSA bacteremia (MRSAB) were included...
August 12, 2016: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/27510635/population-pk-modeling-and-target-attainment-simulations-to-support-dosing-of-ceftaroline-fosamil-in-pediatric-patients-with-absssi-and-cabp
#20
Todd A Riccobene, Tatiana Khariton, William Knebel, Shampa Das, James Li, Alena Jandourek, Timothy J Carrothers, John S Bradley
Ceftaroline, the active form of the pro-drug ceftaroline fosamil, is approved for use in adults with community-acquired bacterial pneumonia (CABP) or acute bacterial skin and skin structure infections (ABSSSI) in the United States and similar indications in Europe. Pharmacokinetic (PK) data from five pediatric (birth to <18 years) studies of ceftaroline fosamil were combined with PK data from adults to update a population PK model for ceftaroline and ceftaroline fosamil. This model, based on a dataset including 305 children, was used to conduct simulations to estimate ceftaroline exposures and percentage of time that free drug concentrations were above the minimum inhibitory concentration (%fT>MIC) for pediatric dose regimens...
August 11, 2016: Journal of Clinical Pharmacology
keyword
keyword
21356
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"